Far too often, medicine today still focuses on treating symptoms rather than identifying and treating the real underlying disease. This can result in inaccurate diagnosis, ineffective treatment, and wasteful spending. Greater diagnostic accuracy is key to expand precision medicine in healthcare. It can help to overcome these problems, making it possible to quickly and reliably differentiate types of diseases and then prescribe effective medical treatment, reducing unnecessary interventions and their associated costs.
Improving diagnostic accuracy depends on improving how you collect and use healthcare data. Data must be of high quality and accurate, tailored to the patient’s individuality and support complex clinical decisions.
There are four data-driven solutions to enable turning healthcare data into insights:
In this interview, Paul Rothman, MD, PhD, Dean of the Medical Faculty & CEO of Johns Hopkins Medicine, United States, explains the challenges they are facing and how they are overcoming them with the creation of Precision Medicine Centers of Excellence (PMCOE).
Click on the image to start the video.
Low-quality data, non-comprehensive data “snapshots”, non-actionable information, and a siloed approach all limit the ability to make precise, data-driven diagnoses. This thought leadership paper describes these challenges and presents four matching approaches to overcoming them, both for COVID-19 and for the practice of medicine.
Deloitte Centre for Health Solutions. 2013. Working differently to provide early diagnosis – Improving access to diagnostics.
PMA P140011/S001 & P140011/S003; Georgian et al. (2019): Can Digital Breast Tomosynthesis Replace Full-Field Digital Mammography? A Multireader, Multicase Study of Wide-Angle Tomosynthesis. AJR 2019, pp. 1-7. doi.org/10.2214/AJR.18.20294
Not available for sale in the U.S. Future availability cannot be guaranteed. Product availability varies by country.
SOMATOM On.site is pending 510(k) clearance and is not yet commercially available in the U.S. Its future availability cannot be ensured.
Some functionalities within teamplay myCare Companion are planned or under development, not commercially available, and their future availability cannot be ensured.
syngo.via can be used as a standalone device or together with a variety of syngo.via based software options, which are medical devices in their own right.
This product is not yet commercially available. Its future availability cannot be ensured.
AI-Rad Companion Brain MR has FDA clearance, and not yet commercially available in all countries.
AI-Pathway Companion Prostate Cancer is not yet commercially available in all countries. Due to regulatory reasons its future availability cannot be guaranteed. AI-Pathway Companion Lung Cancer is under development and not commercially available. Its future availability cannot be ensured.